Several new results and data presentations from Suven Life Science ’s portfolio of investigational neuroscience new chemical entities (NCEs) will be presented at the upcoming Alzheimer’s Association International Conference (AAIC) being held in Vancouver, Canada from July 14-19.
Suven’s portfolio of new molecules, through four mechanisms of action using 5-HT6, 5-HT4, H3 and Neuronal Nicotinic acetylcholine receptors, not only treat cognitive impairment in Alzheimer’s disease symptomatically but are also possibly useful in reducing the disease progression. Suven scientists will be presenting pre-clinical and clinical data on these new molecules and other NCEs pertaining to cognitive impairment and memory related disorders.
In addition to developmental candidate SUVN-502 for Alzheimer’s disease and schizophrenia, Suven Life Science has 12 internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington’s disease, Parkinson’s disease and obesity.
EP News Bureau – Mumbai